TNFSF12 and neoplasm: BIIB023 and RG7212 are both anti-TNFSF12 antibodies to potentially regulate inflammatory processes in neurons and tumor tissues [42, 43], with ongoing clinical investigations (ClinicalTrials.gov identifier NCT01407406 for BIIB023 and NCT01383733 for RG7212).